| dc.contributor | Departament de Salut |
| dc.contributor.author | Programa d'Harmonització Farmacoterapèutica |
| dc.date.accessioned | 2019-08-26T12:33:54Z |
| dc.date.available | 2019-08-26T12:33:54Z |
| dc.date.issued | 2018-10-18 |
| dc.identifier.citation | Programa d'Harmonització Farmacoterapèutica. Atezolizumab per al tractament del carcinoma urotelial localment avançat o metastàtic. Barcelona: Servei Català de la Salut; 2018. |
| dc.identifier.uri | https://hdl.handle.net/11351/4271 |
| dc.description | Urothelial carcinoma; Atezolizumab; Adult patients |
| dc.description.abstract | Urothelial carcinoma (CU) of urinary tract, also known as cell carcinoma transitional of the urinary tract, represents around 85-95% of all the cancers of the urinary tract. The term urothelial refers to the epithelium that covers the urinary tract (uroteli or epithelium of transition), which include the kidney pelvis, ureters, the bladder and two thirds of the urethra. More than 90% of the tumors of the urothelial tract originate in the urinary bladder, while 8% correspond to tumors originating in the renal pelvis and the remaining 2% in urinary and urethra. The incidence of bladder cancer is three times higher in men than in women, with a median age at the diagnosis of 65 years. It is the fifth type of cancer most frequently diagnosed in Spain, only after colon, prostate, lung and breast (fourth in men) |
| dc.language.iso | cat |
| dc.publisher | Servei Català de la Salut |
| dc.relation.ispartof | Programa d'Harmonització Farmacoterapèutica, Servei Català de la Salut |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | Aparell urinari - Càncer - Tractament |
| dc.subject | Medicaments - Assaigs clínics |
| dc.subject | Medicaments antineoplàstics |
| dc.subject.mesh | Urologic Neoplasms |
| dc.subject.mesh | /drug therapy |
| dc.subject.mesh | Drug Evaluation |
| dc.title | Atezolizumab per al tractament del carcinoma urotelial localment avançat o metastàtic |
| dc.type | info:eu-repo/semantics/report |
| dc.subject.decs | neoplasias urológicas |
| dc.subject.decs | /tratamiento farmacológico |
| dc.subject.decs | evaluación de medicamentos |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |